GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (NAS:ISEE) » Definitions » Owner Earnings per Share (TTM)

IVERIC bio (IVERIC bio) Owner Earnings per Share (TTM) : -1.52 (As of Mar. 2023)


View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

IVERIC bio's Owner Earnings per Share (TTM) ended in Mar. 2023 was $-1.52. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for IVERIC bio's Owner Earnings per Share (TTM) or its related term are showing as below:



ISEE's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.37
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

IVERIC bio's Earnings per Share (Diluted) for the three months ended in Mar. 2023 was $-0.53. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.76. It's PE Ratio ratio for today is At Loss.

IVERIC bio's EPS without NRI for the three months ended in Mar. 2023 was $-0.53. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.76. It's PE Ratio without NRI ratio for today is At Loss.


IVERIC bio Owner Earnings per Share (TTM) Historical Data

The historical data trend for IVERIC bio's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio Owner Earnings per Share (TTM) Chart

IVERIC bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 -1.33 -0.81 - -1.52

IVERIC bio Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 -1.19 -1.34 -1.52 -1.52

Competitive Comparison of IVERIC bio's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, IVERIC bio's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IVERIC bio's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IVERIC bio's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where IVERIC bio's Price-to-Owner-Earnings falls into.



IVERIC bio Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

IVERIC bio's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -222.90
Depreciation, Depletion and Amortization 0.19
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.78
Change In Working Capital 14.53
Shares Outstanding (Diluted Average) 137.09

1. Start with "Net Income" from income statement. IVERIC bio's Net Income for the trailing twelve months (TTM) ended in Mar. 2023 was $-222.90 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. IVERIC bio's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2023 was $0.19 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. IVERIC bio's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.78 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

IVERIC bio's 5-Year Average Maintenance Capital Expenditure = $0.78 Mil

5. "Change In Working Capital" is from cashflow statement. IVERIC bio's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2023 was $14.53 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. IVERIC bio's Shares Outstanding (Diluted Average) for the months ended in Mar. 2023 was 137.087 Mil.

IVERIC bio's Onwer Earnings Per Share for Mar. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -222.904 +0.187+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.7752+14.534)/137.087
=-1.52

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=39.95/-1.52
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


IVERIC bio Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of IVERIC bio's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


IVERIC bio (IVERIC bio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, New Jersey, USA, 07054
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.
Executives
Keith Westby officer: SVP & COO ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
David Francis Carroll officer: SVP, CFO and Treasurer ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Glenn Sblendorio director 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Christopher Paul Simms officer: Senior Vice President, CCO FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001
Anthony S Gibney officer: EVP, Chief Business Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Calvin W. Roberts director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Christine Ann Miller director 5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001
Pravin Dugel officer: EVP, Chief Strategy & Business C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
David R Guyer director, officer: Chief Executive Officer ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Jane Henderson director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142